KR100427584B1 - Fungicide composition containing extracts derived from plant - Google Patents
Fungicide composition containing extracts derived from plant Download PDFInfo
- Publication number
- KR100427584B1 KR100427584B1 KR10-2003-0005509A KR20030005509A KR100427584B1 KR 100427584 B1 KR100427584 B1 KR 100427584B1 KR 20030005509 A KR20030005509 A KR 20030005509A KR 100427584 B1 KR100427584 B1 KR 100427584B1
- Authority
- KR
- South Korea
- Prior art keywords
- oil
- fennel
- plant
- extract
- eugenol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/26—Aristolochiaceae (Birthwort family), e.g. heartleaf
- A61K36/268—Asarum (wild ginger)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
본 발명은 식물 추출물을 포함하는 항균제 조성물에 관한 것이다. 특히 본 발명은 병원성 곰팡이의 생육을 저해하는 회향, 대회향, 세신, 녹나무속 식물 및 정향으로 이루어진 군으로부터 선택된 식물에서 추출한 추출물 및 항균성 화합물에 관한 것이다.The present invention relates to an antimicrobial composition comprising a plant extract. In particular, the present invention relates to extracts and antimicrobial compounds extracted from plants selected from the group consisting of fennel, fennel, sessin, camphor and cloves that inhibit the growth of pathogenic fungi.
Description
[발명이 속하는 기술분야][TECHNICAL FIELD OF THE INVENTION]
본 발명은 식물 추출물을 포함하는 항균제 조성물에 관한 것으로서, 더욱 상세하게는 백선균(무좀균)과 칸디다균에 대하여 항균활성을 가지는 회향, 대회향, 세신, 녹나무속 식물 및 정향으로 이루어진 군으로부터 선택된 식물에서 추출한 추출물 또는 화합물을 포함하는 항균제 조성물에 관한 것이다.The present invention relates to an antimicrobial composition comprising a plant extract, and more particularly, extracts from plants selected from the group consisting of fennel, fennel, sessin, camphor and clove having antimicrobial activity against Bacillus aeruginosa (Athletes) and Candida. It relates to an antimicrobial composition comprising an extract or compound.
[종래기술][Private Technology]
진균(곰팡이)에 의해 발생되는 피부질환을 총칭하여 피부진균증(derma-tomycosis)이라 한다. 특히 피부의 각질, 모발, 손톱, 발톱 등의 각질조직에 침입하여 기생하는 피부사상균(dermatophyte)에 의해 발생되는 경우를 피부사상균증(dermato-phytosis), 백선(Tinea) 또는 표재성진균증(superficialfungal infection)이라고 한다.(Ribbon, J. W. (1998) Medical Mycology.InThe pathogenic fungi and the pathogenic actinomyces. 2nd Ed. W.B Saunders Company. Philadelphia, London, Toronto.)Skin diseases caused by fungi (fungus) are collectively called derma-tomycosis. In particular, cases caused by dermatophyte, which invade keratinous tissue such as keratin, hair, nails and toenails of the skin, are called dermato-phytosis, tinea, or superficial fungal infection. and. (Ribbon, JW (1998) Medical Mycology. In The pathogenic fungi and the pathogenic actinomyces. 2nd Ed.. WB Saunders Company. Philadelphia, London, Toronto)
표재성 진균증은 피부 침입부위에 따라 발생부위가 손과 발인 경우 수족족부백선(Tinea manus Tinea pedis), 얼굴인 경우 안면부백선(Tinea faciale), 두부의 경우에는 두부백선(Tinea capitis), 서혜부(사타구니)에 발생했을 때에는 완선(Tinea cruris), 손톱과 발톱의 경우에 조갑백선(Tinea ungium 또는 Onychomy-cosis), 상기부위를 제외한 부위에 발생한 경우를 체부백선(Tinea corporis)이라고 부른다.(Rezabek, G. H. and Friedman, A. D. 1992.Drugs43(5): 674-682.; Kamalam, A. and Thambiah, A. S. 1976.Sabouraudia14(2): 129-148).Superficial mycosis is caused by the incidence of skin in the hands and feet of Tinea manus Tinea pedis, in the face of Tinea faciale, in the head of Tinea capitis, and inguinal groin. In the case of thyroid cruris, tinea ungium or onychomy-cosis in the case of nails and toenails, and cases other than these areas are called tinea corporis (Rezabek, GH and Friedman, AD 1992. Drugs 43 (5): 674-682 .; Kamalam, A. and Thambiah, AS 1976. Sabouraudia 14 (2): 129-148.
표재성 진균증의 주된 원인은 소아포균(microsporum), 표피균(epidermo-phyton), 백색균 (Trichophyton), 칸디다균(candida species), 전풍균(Malassezia furfur)이다. 특히 소아포균(microsporum)은 주로 피부와 체모에 침입하고, 표피균(epider-mophyton)은 피부와 조갑에 침입하며, 백색균 (Trichophyton)은 피부, 체모, 조갑 모두를 침입할 수 있는 특성을 갖고 있다.(Weitzman, I. and Summerbell, R. C. 1995. The dermatophytes. Clinical Microbiology Reviews 8(2): 240-259) 칸디다균은 피부 및 점막에 병변을 일으키고, 전풍균은 반점을 일으키는 전풍(tinea versicolor)의 원인균이 된다.The main causes of superficial mycosis are microsporum, epidermo-phyton, trichophyton, candida species, and Malassezia furfur . In particular, microsporum mainly penetrates the skin and hair, epidermis (epider-mophyton) penetrates the skin and hair, and Trichophyton invades all skin, hair, and hair. (Weitzman, I. and Summerbell, RC 1995. The dermatophytes.Clinical Microbiology Reviews 8 (2): 240-259) Candida bacteria cause lesions on the skin and mucous membranes, and pneumococci cause spots (tinea versicolor). It becomes the causative agent of.
표재성 진균증의 원인균들은 상피세포 상부의 각질조직(keratin)에 기생하여 번식함으로써 표재성 병변을 유발하지만, 때때로 상피 상부이하까지도 염증을 유발할 수도 있고, 백선진(Dermatophytid)을 일으키기도 한다.The causative agents of superficial mycosis are parasitic and multiplying keratin in the upper epithelial cells, causing superficial lesions, but sometimes inferior to the upper epithelium, or dermatophytid.
병원성 곰팡이는 전 세계적인 분포하며, 사람을 포함한 동물에 질병을 유발한다. 병원성 곰팡이는 항상 접촉에 의해 병을 유발시키는 것이 아니고, 감염 곰팡이의 종류, 숙주의 나이, 면역상태, 합병증유무, 피부 건강도, 영양이나 호르몬 상태에 따라 감염여부가 달리 나타난다.(Brasch, J. and Gottkehaskamp, D. 1992. The effect of selected human steroid hormones upon the growth of dermatophytes with different adaptation to man. Mycopathologia 120(2): 87-92)Pathogenic fungi are distributed worldwide and cause disease in animals, including humans. Pathogenic fungi do not always cause disease by contact, but infection depends on the type of fungal infection, the age of the host, the immune status, the presence of complications, the health of the skin, and the nutritional or hormonal status (Brasch, J. and Gottkehaskamp, D. 1992.The effect of selected human steroid hormones upon the growth of dermatophytes with different adaptation to man.Mycopathologia 120 (2): 87-92)
대다수의 더마토파이트 속(Dermatophyte spp)곰팡이에 의한 피부 및 그 부속기 감염을 피부 사상균증(윤선)이라고 한다. 이러한 곰팡이 그룹들은 표피 각화층에 국한되어 서식하며, 일부 종들은 동물 조직 내에 침투하여 서식하기도 한다. 편의상 숙주에 따라, 엔트로필릭(Anthrophillic, 사람기생), 주필릭(Zoophilic, 동물기생), 지오필릭(토양내 기생하는 saprophyte)라 한다.(Gupta, A. K., Einarson, T. R., Summerbell, R. C. and Shear, N. H. 1998. A North American perspective of Drugs. 55(5): 645-674)Infections of the skin and its appendages caused by the majority of the dermatophyte spp fungus are called dermatosis. These fungal groups inhabit only the epidermal keratinous layer, and some species invade and inhabit animal tissues. For convenience, depending on the host, it is referred to as enthrophillic (zoparasitic), zoophilic (zoparasitic), and geophilic (saprophysiological saprophyte) (Gupta, AK, Einarson, TR, Summerbell, RC and Shear). , NH 1998.A North American perspective of Drugs. 55 (5): 645-674)
표재성 진균증의 치료는 원칙적으로 국소 및 전신의 항진균제 사용으로 이루어지며 경우에 따라 각질 용해제의 도포를 병행하여 실시된다. 증상 및 피부병변이 소실된 후에도 약 2-4주간 치료가 요구된다. 그러나, 족부백선의 경우, 환자의 부주의나 신체부위적 특성 및 면역결핍성으로 인하여 치료에 실패하거나 재발할 가능성이 높다.Treatment of superficial mycosis consists in principle of the use of local and systemic antifungal agents, in some cases in parallel with the application of keratolytic agents. Treatment is required for about 2-4 weeks after the disappearance of symptoms and skin lesions. However, tinea ringworm is highly likely to fail or relapse due to carelessness, disposition of the body, and immunodeficiency.
지금까지 많은 항진균제들이 피부진균증을 치료하기 위해 이용되어 왔으나,재발비율이 높고 피부독성에 대한 인식 증가로 인해 보다 안전하고 우수한 항진균물질을 천연물에서 찾으려는 노력이 이루어지고 있다.Until now, many antifungal agents have been used to treat skin fungi, but due to the high recurrence rate and increased awareness of skin toxicity, efforts have been made to find safer and better antifungal substances in natural products.
따라서, 본 발명은 진균에 대하여 항균활성을 가지는 식물 추출물을 제공하는 것을 목적으로 한다.Therefore, an object of the present invention is to provide a plant extract having antibacterial activity against fungi.
또한 본 발명은 백선균 또는 칸디다균에 대하여 항균활성을 가지는 식물 추출물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a plant extract having antibacterial activity against ringworm or Candida.
또한 본 발명은 백선균 또는 칸디다균에 대하여 항균활성을 가지는 식물유래 화합물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide a plant-derived compound having antibacterial activity against ringworm or candida.
또한 본 발명은 피부에 안정하며 우수한 항진균성을 가지는 항진균제 조성물을 제공하는 것을 목적으로 한다.It is another object of the present invention to provide an antifungal drug composition that is stable to the skin and has excellent antifungal properties.
도 1은 정향 메탄올 추출물에서 유제놀을 분리하는 과정을 도시한 것이고,1 illustrates a process for separating eugenol from a clove methanol extract,
도 2는 정향유에서 유제놀 및 이소유제놀을 분리하는 과정을 도시한 것이다.2 shows a process for separating eugenol and isoeugenol from clove oil.
상기 목적을 달성하기 위하여 본 발명은 회향, 대회향, 세신, 녹나무속 식물 및 정향으로 이루어진 군으로부터 1종이상 선택된 식물에서 추출한 추출물을 포함하는 항균제 조성물을 제공한다.In order to achieve the above object, the present invention provides an antimicrobial composition comprising an extract extracted from at least one plant selected from the group consisting of fennel, fennel, sessin, camphor and cloves.
또한 본 발명은 펜촌, 유제놀, 이소유제놀, 메틸유제놀, 신나밀알콜 및 신남알데하이드로 이루어진 군으로부터 1종 이상 선택된 화합물을 포함하는 항균제 조성물을 제공한다.The present invention also provides an antimicrobial composition comprising at least one compound selected from the group consisting of phenchon, eugenol, isoeugenol, methyl eugenol, cinnamil alcohol and cinnanamaldehyde.
이하 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 회향, 세신, 녹나무속 식물 및 정향이 항진균 활성을 가짐을확인하고 본 발명을 완성하였다.The inventors have confirmed that fennel, sessin, camphor and clove have antifungal activity and have completed the present invention.
회향(Foeniculum vulgare)은 대회향, 일명 팔각회향(Illicium verum)과 주요성분들이 거의 동일한 것으로 알려져 있다.(김창민, 신민교, 안덕균, 이경순 등. 1998. 중약대사전, vol. 9, 정담출판사, 5813-5816; vol. 10, 6597-6603.)Fennel ( Foeniculum vulgare ) is known to be almost the same as the main components of the scented thyme, also known as octagonal fennel ( Illicium verum ) (Kim Chang-min, Shin Mingyo, Ahn Deok-kyun, Lee Kyung-soon, etc. 1998. Chinese Medicine Dictionary, vol. ; vol. 10, 6597-6603.)
녹나무속 식물로는 육계(Cinnamomum sieboldii), 계피(C. cassia), 실론육계(C. zeylanica), 계수나무 및 육계나무(C. laureirii)가 있다. 한방에서는 녹나무과의 식물의 박피(뿌리, 줄기, 가지) 중 두껍게 껍질을 벗겨 건조시킨 것을 육계, 그 보다 작은 가지의 껍질을 벗겨 건조한 것을 계피, 그리고 아주 가느다란 가지의 껍질을 건조시킨 것을 계지라고 한다. 또한 녹나무과의 녹나무속(Cinnamomum)의 수피를 벗겨서 건조시킨 것을 계피 또는 육계라 칭한다.Camphor plants include Cinnamomum sieboldii , Cinnamon C. cassia , C. zeylanica , Cassia and C. laureirii . In Chinese medicine, the peeled and dried bark of the camphor plant (root, stem, and eggplant) is dried, and the bark of smaller branches is dried, cinnamon, and the very thin eggplant is dried. . Also, peeled and dried bark of the Camphor tree of Cinnamomum ( Cinnamomum ) is called cinnamon or broiler.
상기 정향은 유제니아 카리오필라타(Eugenia caryophyllata) 또는 시지기움 마로마티컴(Syzygium aromaticum)으로, 상기 식물체의 정유는 정향유로 상용화되고 있으며, 특히 클로브 버드 오일(clove bud oil)은 정향의 꽃봉오리만을 채집하여 얻은 식물체 정유이다.The clove is Eugenia caryophyllata or Syzygium aromaticum , the essential oil of the plant is commercialized as clove oil, in particular, clove bud oil (clove bud oil) only collect the buds of the clove Plant essential oil obtained by.
본 발명의 식물들은 통상의 추출방법으로, 바람직하게는 식물 분쇄물을 증류수, 알콜 또는 유기용매에 혼합하고, 분획한 다음 용매를 건조시켜 식물 추출물을 제조한다. 알콜은 탄소수 1 내지 5가 바람직하며, 더욱 바람직하게는 에탄올, 메탄올, 프로판올 또는 부탄올이며, 가장 바람직하게는 메탄올이다. 유기용매는 헥산, 클로로포름 또는 에틸아세테이트가 바람직하며, 가장 바람직하게는 헥산이다. 추출부위는 식물의 꽃, 엽, 줄기, 꽃봉우리, 뿌리, 수지, 열매, 종자, 식물체 등에서 추출되며, 회향 추출물은 회향열매 추출물이 바람직하고, 세신 추출물은 세신 뿌리 추출물이 바람직하고, 녹나무속 추출물 및 정향 추출물은 뿌리 추출물이 바람직하다. 그러나, 상기에 기재한 바람직한 추출부위에 한정되는 것은 아니다.The plants of the present invention are prepared by a conventional extraction method, preferably by mixing plant comminutes with distilled water, alcohol or an organic solvent, fractionating and drying the solvent. The alcohol preferably has 1 to 5 carbon atoms, more preferably ethanol, methanol, propanol or butanol, and most preferably methanol. The organic solvent is preferably hexane, chloroform or ethyl acetate, most preferably hexane. Extraction part is extracted from the flowers, leaves, stems, buds, roots, resins, fruits, seeds, plants of plants, etc.Fennel extract is preferably fennel extract, Sessin extract is preferably Sessin root extract, Camphor extract And clove extract is preferably a root extract. However, it is not limited to the preferable extraction site described above.
또한 본 발명의 식물들은 정유로 제조할 수 있다. 식물 정유는 통상의 정유 추출법으로 추출하거나, 시판되는 정유를 구입하여 사용할 수 있다. 대표적인 추출법은 물이나 수증기를 이용한 증류법과 압착법이 있다. 시판되는 정유에는 펜낼 스위트 오일(회향유), 신나먼 오일(계피유) 및 클로브 버드 오일(정향유)이 있다.The plants of the present invention can also be prepared with essential oils. Plant essential oils can be extracted by a conventional essential oil extraction method, or a commercial oil can be purchased and used. Representative extraction methods include distillation using water or steam and compression. Commercial essential oils include Pennyl Sweet Oil (Fennel Oil), Cinnamon Oil (Cinnamon Oil), and Clove Bud Oil (Clove Oil).
본 발명의 식물 추출물 또는 정유는 무좀을 유발하는 백선균 및 칸디다균에 적용하여 생육 저해환(Clear zone)을 측정한 결과 모두 우수한 항진균 활성을 나타내었으며, 그중 세신 추출물, 정향 추출물, 계피유 및 정향유가 보다 높은 항진균 활성을 나타내었다.The plant extract or essential oil of the present invention showed excellent antifungal activity as a result of measuring the clear zone by applying to the fungus-induced ringworm and Candida fungi, among which the sericin extract, cloves extract, cinnamon oil and cloves oil were better. It showed high antifungal activity.
또한 본 발명은 식물유래 항진균성 화합물을 제공한다. 항진균성 화합물은 정향 유래 화합물인 유제놀 및 이소유제놀, 회향 유래 화합물인 펜촌, 육계 유래 화합물인 신나밀알콜 및 신남 알데하이드, 및 메틸유제놀을 포함한다. 상기 항진균성 화합물은 시판되는 화합물을 구입하여 사용할 수 있으며, 상기 식물로부터 공지된 기술로 분리, 정제할 수 있다.The present invention also provides plant-derived antifungal compounds. Antifungal compounds include eugenol and isoeugenol, which are clove-derived compounds, fenchon, which is a fennel-derived compound, cinnamil alcohol and cinnamic aldehyde, which are broiler-derived compounds, and methyl eugenol. The antifungal compound may be purchased by using a commercially available compound, and may be separated and purified from the plant by a known technique.
본 발명은 식물 추출물 또는 항진균성 화합물을 포함하는 항균제 조성물을 제공한다. 상기 항균제 조성물은 병원성 곰팡이에 대하여 생육억제 활성을 가지는 것으로, 바람직하게는 백선균 또는 칸디다균에 대하여 생육 저해 활성을 갖는다.The present invention provides an antimicrobial composition comprising a plant extract or an antifungal compound. The antimicrobial composition has growth inhibitory activity against pathogenic fungi, and preferably has growth inhibitory activity against ringworm or candida.
본 발명의 항진균제 조성물은 하기 표 1로 기재한 병원성 곰팡이에 대하여항균효과를 가진다. 대표적인 병원성 곰팡이는 트리코피톤 루프럼(Trichophyton rubrum, KCTC 6345), 미코스포럼 오더이니(Micosporum audouinii, KCTC 6346), 트리코피톤 페러기네움(Trichophyton ferrugineum, KCTC6351), 에피더모피톤 플로코섬(Epidermophyton floccosum, KCTC 6586), 트리코피톤 멘타그로피테스(Trichophyton mentagrophytes, KCTC 6077) 및 칸디다 알비칸스(Candida albicans, KCTC 6586)이다.The antifungal composition of the present invention has an antifungal effect against the pathogenic fungus described in Table 1 below. Representative pathogenic fungi include Trichophyton rubrum (KCTC 6345), Micosporum audouinii (KCTC 6346), Trichophyton ferrugineum (KCTC6351), Epidermophyton floccosum a KCTC 6586), tricot piton menta thereof blood test (Trichophyton mentagrophytes, KCTC 6077) and Candida albicans (Candida albicans, KCTC 6586).
본 발명의 항진균제 조성물은 병원성 곰팡이의 생육억제를 위한 용도로 사용할 수 있으며, 바람직하기로는 세정제, 무좀 등의 피부진균증(derma-tomycosis) 치료제, 소독제 등으로 사용될 수 있다.The antifungal composition of the present invention can be used for the purpose of inhibiting the growth of pathogenic fungi, and preferably, it can be used as an agent for treating derma-tomycosis such as athlete's foot, athlete's foot, and disinfectant.
항진균제 조성물의 제제(製劑)는 경고제(硬膏劑), 과립제(顆粒劑), 로션제(lotiones) , 리니멘트제(liniments), 리모나데제(limonades), 방향수제(芳香水劑), 산제(散劑), 시럽제(syrups), 안연고제(眼軟膏劑), 액제(液劑), 에어로솔제(aerosols), 엑스제(extracts), 엘릭실제(elixier), 연고제(軟膏劑), 유동(流動)엑스제, 유제, 현탁제, 침제(浸劑), 전제(煎劑),점안제(點眼劑), 정제(錠劑), 좌제(坐劑), 주사제, 주정제(酒精劑), 카타플라스마제(cataplasma), 캡슐제(capsules), 크림제, 트로키제(troches), 틴크제(tincture), 파스타제(pasta) 또는 환제(丸劑)가 바람직하나, 상기 제제에 한정되지 않는다.Formulations of antifungal composition include warning agents, granules, lotions, liniments, limonades, fragrances and powders. Syrups, ophthalmic ointments, liquids, aerosols, extracts, elixiers, ointments, fluids X), emulsion, suspension, acupuncture, premise, eye drops, tablets, suppositories, injectables, spirits, kata Plasma, capsules, cream, troches, tincture, pasta or pills are preferred, but not limited to the above formulations.
항진균제 조성물은 제제 및 사용방법에 따라 생리약학적으로 허용가능한 담체를 더욱 포함할 수 있으며, 항진균제 조성물 내 식물 추출물 또는 정유의 함량은 1 내지 20 중량 %가 바람직하다. 항진균제 조성물의 투여량은 1일 10 내지 50 mg으로 1회 내지 3회 실시하는 것이 바람직하나, 병의 중한 정도 및 환자의 건강상태에 따라 조절하는 것이 더욱 바람직하다.The antifungal composition may further include a physiologically acceptable carrier according to the formulation and the method of use, and the content of the plant extract or the essential oil in the antifungal composition is preferably 1 to 20% by weight. The dose of the antifungal agent is preferably administered once to three times at 10 to 50 mg per day, but more preferably adjusted according to the severity of the disease and the health of the patient.
이하 본 발명의 실시예를 기재한다. 하기 실시예는 본 발명을 예시하기 위한 것일 뿐 본 발명이 하기 실시예에 한정되는 것은 아니다.Hereinafter, examples of the present invention will be described. The following examples are only for illustrating the present invention and the present invention is not limited to the following examples.
실시예 1: 항균성 식물 추출물 제조Example 1 Preparation of Antimicrobial Plant Extracts
회향(Foeniculum vulgare)의 열매, 세신(Asarum heterotropoides)의 뿌리, 육계(Cinnamomum sieboldii) 또는 정향(Eugenia caryophyllata)의 꽃봉오리, 계피를 구입하였고, 각각에 대하여 메탄올 추출물을 수득하였다. 메탄올 추출물 제조방법은 모두 동일하게 실시하였고, 일예로 회향의 열매 메탄올 추출방법을 나타내었다.Fruits of fennel ( Foeniculum vulgare ), roots of Asarum heterotropoides , buds of broiler ( Cinnamomum sieboldii ) or cloves ( Eugenia caryophyllata ) and cinnamon were purchased and methanol extracts were obtained for each. Methanol extract manufacturing method was carried out in the same manner, as an example showed a fruit methanol extraction method of fennel.
회향(Foeniculum vulgare) 열매 300 g을 믹서기로 곱게 마쇄하고, 500 ml 삼각플라스크에 넣은 다음 메탄올 200 ml을 혼합하여 실온 암실에서 2일간 방치하였다. 2일 후 감압여과하여 얻은 여과액을 회전진공농축기(EYELA autojack NAJ-160, Japan)로 농축하였다. 여과지에 걸러진 마쇄물은 다시 메탄올에 혼합하는 과정을 거쳐 최종적으로 메탄올 추출물을 제조하였다.300 g of Foeniculum vulgare fruit was ground finely in a blender, placed in a 500 ml Erlenmeyer flask, mixed with 200 ml of methanol, and left in a dark room at room temperature for 2 days. After 2 days, the filtrate obtained by filtration under reduced pressure was concentrated using a rotary vacuum concentrator (EYELA autojack NAJ-160, Japan). The filtered material filtered through the filter paper was again mixed with methanol to finally prepare a methanol extract.
실시예 2: 항균성 식물 정유의 제조Example 2: Preparation of Antimicrobial Plant Essential Oils
진아향료(주) 회향유, 육계유, 계피유, 정향유를 구입하였다.Jinhyang Co., Ltd. Fennel oil, broiler oil, cinnamon oil, clove oil were purchased.
상기 정유는 증류법(steam distillation)으로 제조한 것이다. 소량의 증류수와 회향, 육계 및 정향 각각을 믹서로 곱게 마쇄하여 3 L 농축플라스크에 넣었다. 가열멘틀(heating mentle)상에서 상기 플라스크의 멘틀 온도를 약 70 ℃로 하고, 디에틸에테르(diethyl ether)와 헥산이 각각 40 ml(1/1, v/v)씩 담긴 플라스크의 멘틀 온도를 30∼40 ℃(약 38℃)로 하여 2시간 동안 가열하였다. 한번 증류하는데 필요한 시료의 양은 250 g로 하고 추출 후 추출물 내에 함유된 수분을 제거하기 위해 무수황산나트륨(Na2SO4)을 소량 넣은 다음 데시케이터(desiccator)에 방치하였고 이후 여지(Toyo No. 2)에 걸러 농축하였다.The essential oil is prepared by steam distillation. A small amount of distilled water, fennel, broiler, and clove were each finely ground in a mixer and placed in a 3 L concentrated flask. The flask's mantle temperature is about 70 ° C. on a heating mentle, and the flask's mantle temperature is 30 to 40 ml (1/1, v / v) containing diethyl ether and hexane, respectively. It heated at 40 degreeC (about 38 degreeC) for 2 hours. The amount of sample required for distillation once was 250 g, and after extraction, a small amount of anhydrous sodium sulfate (Na 2 SO 4 ) was added to remove moisture contained in the extract, and then left in a desiccator. ), And concentrated.
실시예 3: 곰팡이의 생육저해활성 측정Example 3 Measurement of Growth Inhibition Activity of Mold
한국 유전자은행(Korean Collection for Type Cultures, KCTC)으로부터 트리코피톤 루프럼(Trichophyton rubrum, KCTC 6345), 미코스포럼 오더이니(Micosporum audouinii, KCTC 6346), 트리코피톤 페러기네움(Trichophyton ferrugineum, KCTC6351), 에피더모피톤 플로코섬(Epidermophyton floccosum, KCTC 6586), 트리코피톤 멘타그로피테스(Trichophyton mentagrophytes, KCTC 6077), 칸디다 알비칸스(Candida albicans, KCTC 6586) 6종을 분양받았다. 곰팡이 생육저해활성은 여지확산법(Paper disc diffusion method)으로 검정하였다. Trichophyton rubrum (KCTC 6345), Micosporum audouinii (KCTC 6346), Trichophyton ferrugineum ( KCTC6351 ) from the Korean Collection for Type Cultures (KCTC), epi koseom more fur tone flow (Epidermophyton floccosum, KCTC 6586), tricot piton menta thereof blood test (Trichophyton mentagrophytes, KCTC 6077), Candida albicans (Candida albicans, KCTC 6586) was pre-sale 6 species. Inhibitory activity of fungi was assayed by the paper disc diffusion method.
분양받은 균주를 사보라우드 한천(Sabouraud's agar) 배지에 접종한 후 각 메탄올 추출물(실시예 1)을 메탄올에 녹이거나 정유(실시예 2) 자체를 직접 여지(paper disc)에 처리하였다. 여지를 각 균이 접종된 상기 배지에 올려놓고 28 ℃에서 5일간 호기배양 한 후, 여지 주위에 형성된 생육저해환(clear zone)의 크기를 보고 항균활성을 확인하였다.After the inoculated strains were inoculated in Sabouraud's agar medium, each methanol extract (Example 1) was dissolved in methanol, or the essential oil (Example 2) was treated directly on a paper disc. After cultivation in the medium was inoculated with each strain and incubated at 28 ℃ for 5 days, the antibacterial activity was confirmed by looking at the size of the growth zone (clear zone) formed around the margin.
하기 표 2는 메탄올 추출물과 정유에 대한 여지당 적정농도를 처리하였을 때, 백선균 5종과 칸디다균 1종에 대해 보이는 생육저해활성을 측정하여 나타낸 것이다.Table 2 below shows the measured inhibitory activity against virulent Bacillus spp. And Candida spp. When treated with methanol extract and the optimal concentration per room for essential oil.
메탄올 추출물 또는 정유에 의한 생육저해환의 크기가 10 mm 이상으로 나타난 경우 곰팡이 생육저해활성을 가지는 것으로 판단하였다. 상기 표 2에 제시된 바와 같이, 미코스포럼 오디이니에 대해 회향 메탄올 추출물 50 mg 처리시 항균활성을 나타내었고, 회향유는 여지당 100 mg과 50 mg 처리시 항균활성을 나타내었으며, 세신은 10 mg 이상 처리시 항균활성을 보였다. 또한 육계 메탄올 추출물 및 육계유는 각각 10 mg과 50 mg 처리시 아주 강한 생육 저해환을 형성하였고, 정향 메탄올 추출물 및 정향유 역시 10 mg 처리시 매우 넓은 저해환을 형성하였다. 이러한 항균활성은 나머지 진균들에서도 비슷한 양상을 보였다.When the size of the growth inhibition ring by methanol extract or essential oil was 10 mm or more, it was determined to have fungal growth inhibition activity. As shown in Table 2, the antimicrobial activity of 50 mg of fennel methanol extract showed an antimicrobial activity for the medicinal extract of fennel methanol, and the fennel oil exhibited the antimicrobial activity of 100 mg and 50 mg per litter, and the sessin was more than 10 mg. When treated, it showed antimicrobial activity. In addition, broiler methanol extract and broiler oil formed very strong growth inhibitory rings when treated with 10 mg and 50 mg, respectively. Clove methanol extract and clove oil also formed very broad inhibitory rings when treated with 10 mg. This antimicrobial activity was similar in the other fungi.
실시예 4: 항진균성 화합물의 분리Example 4: Isolation of Antifungal Compounds
(1) 유제놀 분리(1) Eugenol Separation
정향 메탄올 추출물(20 g)을 헥산(800 ml), 클로로포름(800 ml), 에틸아세테이트(800 ml), 물층으로 분획하여 헥산 12.6 g, 클로로포름 3.8 g, 에틸아세테이트 0.8 g 및 물층 2.4 g을 수득하였다. 각 분획에 대한 항균활성을 검정하였고, 헥산분획이 항균활성을 나타냄을 확인하였다.Clove methanol extract (20 g) was partitioned into hexane (800 ml), chloroform (800 ml), ethyl acetate (800 ml) and water layer to give 12.6 g of hexane, 3.8 g of chloroform, 0.8 g of ethyl acetate and 2.4 g of water layer. . The antimicrobial activity of each fraction was assayed and it was confirmed that the hexane fraction showed antimicrobial activity.
헥산 분획 12.6 g을 실리카겔칼럼(Merck 230 mesh, 600g, 직경 5.5 x 70 cm)으로 색층분석하고, 헥산-에틸아세테이트로 순차분획(stepwise gradient, 헥산: 에틸아세테이트(5:1 ->3:1, v/v))하여 용출물들을 수득하였다. 용출물들은 TLC(Thin layer chromatography)을 실시하여 동일한 스팟으로 확인되면 합쳐서 농축하여 H1(1.4 g), H2(27. g), H3(0.4 g), H4(0.2 g)로 분리하였다. 각 분획들에 대한 항균활성을 검정한 결과 H1과 H2가 항균활성을 나타내었다. 이후 H2가 H1에 비하여 많은 수득율을 보여, H2를 대상으로 항균활성 물질을 분리하였다.12.6 g of the hexane fraction was chromatographed on a silica gel column (Merck 230 mesh, 600 g, 5.5 x 70 cm in diameter) and stepwise gradient (hexane: ethyl acetate (5: 1-> 3: 1, v / v)) to eluate. The eluates were separated by concentration of H1 (1.4 g), H2 (27. g), H3 (0.4 g), and H4 (0.2 g) by TLC (Thin layer chromatography). As a result of assaying the antimicrobial activity of each fraction, H1 and H2 showed antimicrobial activity. Since H2 shows a much higher yield than H1, the antimicrobial active material was separated from H2.
H2는 고속액체크로마토그라피(Spectra System P2000)를 실시하였다. 칼럼(μPorasil, 내경 19 mm x 길이 300 mm)에 분당 3 ml의 속도로 헥산:에틸아세테이트 (9:1, v/v) 용매를 흘려주었고, 용출물은 242 nm에서 검출하여 화합물 I을 수득하였다. 화합물 I은 EI-MS,1H와13C-NMR 등의 분광분석에 기초하여 분석한 결과 화학식 1의 유제놀(eugenol)로 동정되었다.H2 was subjected to high performance liquid chromatography (Spectra System P2000). Hexane: ethyl acetate (9: 1, v / v) solvent was flowed into the column (μPorasil, inner diameter 19 mm x length 300 mm) at a rate of 3 ml per minute, and the eluate was detected at 242 nm to obtain compound I. . Compound I was identified as eugenol of Formula 1 by analysis based on spectroscopic analysis such as EI-MS, 1 H and 13 C-NMR.
[화학식 1][Formula 1]
(2) 정향유에서 이소유제놀과 유제놀의 분리(2) Separation of isoeugenol and eugenol from clove oil
정향유 1 mg에서 이소유제놀과 유제놀을 분리하였다.(도 2)Isoeugenol and eugenol were separated from 1 mg of clove oil (FIG. 2).
정향유를 분석용 고속액체크로마토그라피(analytical HPLC, μPorasil:직경 10 ㎛, 내경 3.9 mm x 길이 300 mm)에서 분당 2 ml, 흡광도 242nm, 용매조건 헥산:에틸아세테이트 9:1(v/v)에서 이소유제놀과 유제놀을 분리하였다. 동일한 조건하에서 분취용 칼럼(μPorasil, 레진직경 10 ㎛, 내경 19 mm x 길이 300 mm) 사용하여 화합물 H1, H2, H3을 정제하였다. 3종의 화합물(H1, H2, H3)에 대한 항균활성을 검정하였고, 항균활성 화합물 H2와 H3을 확인하였다.Clove oil is analyzed by high-performance liquid chromatography (analytical HPLC, μPorasil: 10 μm in diameter, 3.9 mm in diameter x 300 mm in length), 2 ml per minute, absorbance 242 nm, solvent condition hexane: ethyl acetate 9: 1 (v / v). Eugenol and eugenol were separated. Under the same conditions, compounds H1, H2, H3 were purified using a preparative column (μPorasil, resin diameter 10 μm, internal diameter 19 mm x length 300 mm). The antimicrobial activity of three compounds (H1, H2, H3) was assayed, and the antimicrobial active compounds H2 and H3 were identified.
시그마(Sigma)에서 이소유제놀과 유제놀을 구입하였고, 이소유제놀과 유제놀의 표준품과 EI-MS을 H2 및 H3과 비교하였다. 그 결과 H2는 유제놀로 동정되었고, H3은 이소유제놀로 동정되었다. 이소유제놀은 화학식 2로 표현된다.Isoeugenol and eugenol were purchased from Sigma, and the standards of isoeugenol and eugenol and EI-MS were compared with H2 and H3. As a result, H2 was identified as eugenol and H3 was identified as isoeugenol. Isoeugenol is represented by the formula (2).
[화학식 2][Formula 2]
실시예 5: 화합물의 항진균성 검정Example 5: Antifungal Assay of Compounds
유제놀, 이소유제놀에 대한 항진균 활성을 검정하였고, 그 외 회향유 유래 펜촌 및 육계 유래 신나밀알콜과 신남알데하이드의 항진균 활성을 동일하게 검정하였다.The antifungal activity of eugenol and isoeugenol was assayed, and the antifungal activity of cinnamon-derived fenchon-derived broiler-derived cinnamic alcohol and cinnamic aldehyde was also tested.
상기 표 3에서, 클로트리미졸은 양성대조군이다. 미코스포럼 오더이니에 대하여 펜촌은 여지당 50 mg 처리시 강한 저해활성을 나타내었고, 유제놀과 이소유제놀은 10 mg 처리시 매우 강한 저해활성을 나타내었으며, 신나밀알콜은 전체적으로 25 mm 이상에서 강한 저해활성을 나타내었다. 신남알데하이드, 메틸유제놀은 가장 강한 항진균 활성을 나타내었다. 각 화합물들의 저해활성환의 크기는 처리 농도 및 균주에 따라 약간의 차이를 보이지만, 전체적인 생육저해활성에 있어서는 비슷한 양상을 보였다.In Table 3, clotrimizol is a positive control. Pencoin showed strong inhibitory activity at 50 mg treatment, Eugenol and Isoeugenol showed very strong inhibitory activity at 10 mg treatment. It showed strong inhibitory activity. Cinnamic aldehyde and methyl eugenol showed the strongest antifungal activity. The size of the inhibitory ring of each compound was slightly different depending on the treatment concentration and strain, but showed similar pattern in overall growth inhibition activity.
실시예 6: 임상실험Example 6: Clinical Trials
(1) 회향유에 대한 임상실험(1) Clinical trial on fennel oil
회향유를 에탄올에 녹여 5 %로 회향유 조성물을 제조한 다음 무좀균에 의해 족부가 감염된 5명의 성인 남성을 대상으로 임상실험을 하였다.Fennel oil was dissolved in ethanol to prepare a fennel oil composition at 5%, and then clinical trials were conducted in five adult men infected with foot fungus by athlete's foot.
회향유 조성물은 매일 3초 동안 1회 발에 분무하여(회향유 성분이 0.15 g 처리된 수준) 무좀균의 진전경과를 시간별로 조사하였다.The fennel oil composition was sprayed into the foot once every three seconds (at a level of 0.15 g of the fennel oil component) to investigate the progress of athlete's foot over time.
무좀이 심한 사람의 경우 사용시간에 따라 하기의 양상이 나타났다.For athletes with severe athlete's foot, the following pattern appeared according to usage time.
(1) 처리 1일: 갈라지고 습진과 같이 진눌린 상피세포 또는 조직에서 나오는 진물이 사라졌다.(1) Treatment Day 1: The oozing from the epithelial cells or tissues cracked and crushed like eczema disappeared.
(2) 처리 2일: 갈라진 부위가 서서히 아물었다.(2) Day 2 of treatment: The cracked site gradually healed.
(3) 처리 3일: 무좀 부위의 각질이 형성되고, 무좀 부위에서의 통증이 사라졌다.(3) Day 3 of treatment: keratin was formed at the athlete's foot, and pain at the athlete's foot disappeared.
(4) 처리 4일: 각질의 형성이 매우 두드러져 완전히 치유된 양상을 보였다.(4) Day 4 treatment: The formation of keratin was very prominent, showing complete healing.
무좀이 심하지 않은 사람의 경우 1일 2회 처리로도 충분한 각질형성을 유도하여 무좀의 완치가 가능하였다.In case of athlete's foot, it was possible to cure athlete's foot by inducing enough keratin formation even twice a day.
또한 회향유의 도포하는 기간 중에 환자의 피부에 별다른 병반 및 부작용이 관찰되지 않았다.In addition, no lesions and side effects were observed on the skin of the patient during the application of the fennel oil.
따라서, 회향유 조성물은 무좀이 형성된 조직의 각질화를 야기시켜 백선균의 생육조건의 변화를 가져오며, 무좀을 치료한다.Therefore, the fennel oil composition causes keratinization of the athlete's foot-forming tissues, thereby bringing about changes in the growth conditions of ringworm, and treating athlete's foot.
본 발명은 회향, 대회향, 세신, 녹나무속 식물 및 정향에서 항균성 추출물을 분리하였고, 항균성 화합물 펜촌, 유제놀, 이소유제놀, 메틸유제놀, 신나밀알콜 및 신남알데하이드를 동정하였다. 상기 항균성 추출물 및 항균성 화합물은 백선균과 칸디다균에 대해 매우 강한 항균활성을 가지므로 독성이 없는 천연항균제로서 이용가능성이 매우 높다.The present invention isolated antibacterial extracts from fennel, fennel, sessin, camphor and clove, and identified the antimicrobial compounds Fenchon, Eugenol, Isoeugenol, Methyl Eugenol, Cinnamil Alcohol and Cinnanamaldehyde. Since the antimicrobial extract and the antimicrobial compound have very strong antimicrobial activity against ringworm and Candida, it is highly applicable as a natural antimicrobial agent without toxicity.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0005509A KR100427584B1 (en) | 2003-01-28 | 2003-01-28 | Fungicide composition containing extracts derived from plant |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2003-0005509A KR100427584B1 (en) | 2003-01-28 | 2003-01-28 | Fungicide composition containing extracts derived from plant |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2002-0054685A Division KR100387939B1 (en) | 2002-09-10 | 2002-09-10 | Fungicide composition containing extracts derived from plant |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20030036268A KR20030036268A (en) | 2003-05-09 |
KR100427584B1 true KR100427584B1 (en) | 2004-04-28 |
Family
ID=29578448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2003-0005509A KR100427584B1 (en) | 2003-01-28 | 2003-01-28 | Fungicide composition containing extracts derived from plant |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR100427584B1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100769669B1 (en) * | 2005-09-15 | 2007-10-23 | 충남대학교산학협력단 | A Composition comprising methyl eugenol for control of Botrytis cinerea |
KR101069907B1 (en) * | 2008-09-04 | 2011-10-05 | 재단법인 제주테크노파크 | A composition for skin whitening comprising extract, fraction or compound from Lindera erythrocarpa |
KR200452190Y1 (en) * | 2008-11-12 | 2011-02-10 | 박복원 | Steam inhaler |
-
2003
- 2003-01-28 KR KR10-2003-0005509A patent/KR100427584B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
KR20030036268A (en) | 2003-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mohammadhosseini | The ethnobotanical, phytochemical and pharmacological properties and medicinal applications of essential oils and extracts of different Ziziphora species | |
Shah et al. | Piper betle: Phytochemical, pharmacological and nutritional value in health management | |
Sabandar et al. | Medicinal property, phytochemistry and pharmacology of several Jatropha species (Euphorbiaceae): a review | |
Rajvaidhya et al. | A review on Acacia arabica-an Indian medicinal plant | |
US20030091669A1 (en) | Composition comprising wenguanguo extracts, methods for preparing same and uses thereof | |
Pandey et al. | Essential oil compositions, pharmacological importance and agro technological practices of Patchouli (Pogostemon cablin Benth.): A review | |
JP5328656B2 (en) | Cinnamomi and poria compositions and uses thereof | |
Aboluwodi et al. | Chemical constituents and anti-inflammatory activity of essential oils of Datura stramonium L | |
KR20020008809A (en) | Fungicide composition containing extracts derived from plant | |
Mohanty et al. | A review on therapeutic potential of Artemisia nilagirica | |
Dongare et al. | A Review on Pogostemon patchouli | |
Arora et al. | Cinnamon: a clinical approach as multifarious natural remedy with absolute immunity | |
Mansour-Djaalab et al. | In vitro evaluation of antifungal effects of Lawsonia inermis, Pistacia lentiscus and Juglans regia. | |
Rauf et al. | Pharmacological investigation of genus Pistacia | |
KR100387939B1 (en) | Fungicide composition containing extracts derived from plant | |
KR100427584B1 (en) | Fungicide composition containing extracts derived from plant | |
KR100437576B1 (en) | Fungicide composition containing cinnamylalcohol | |
KR100807809B1 (en) | Antimicrobial composition which comprising the Hibiscus ethanol extract | |
PT117531B (en) | PRODUCT WITH EUCALYPTUS GLOBULUS COMPONENTS FOR USE AS AN ANTIFUNGAL, ANTI-INFLAMMATORY AND ANTI-SENESCENT FOR TOPICAL APPLICATION IN THE ABSENCE OF CYTOTOXICITY | |
CN113713003A (en) | Folium artemisiae argyi extract and preparation method and application thereof | |
Singh et al. | Exploring the Pharmacological potential and Bioactive components of Pogostemon cablin (Blanco) Benth, Traditional Chinese Medicine | |
KR100649121B1 (en) | Complex antifungal agents as an effective gredient comprising essential oil compounds from Agastache rugosa and ketoconazole | |
WO2003035093A1 (en) | Antibacterial composition comprising plant extract | |
KR20050083116A (en) | Antifungal composition | |
Tunan | Phytochemical investigation of Nymphaea Pubescens and study of its antimicrobial activities |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A107 | Divisional application of patent | ||
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130405 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20140401 Year of fee payment: 11 |
|
LAPS | Lapse due to unpaid annual fee |